Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Muscle dysfunction in cancer patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiovascular and metabolic health effects of team handball training in overweight women: Impact of prior experience

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Psychological stress in long-term testicular cancer survivors: a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Behandling af tymom og thymuskarcinom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Muscle dysfunction is a prevalent phenomenon in the oncology setting where patients across a wide range of diagnoses are subject to impaired muscle function regardless of tumor stage and nutritional state. Here, we review the current evidence describing the degree, causes and clinical implications of muscle dysfunction in cancer patients. The efficacy of exercise training to prevent and/or mitigate cancer-related muscle dysfunction is also discussed.

DESIGN: We identified 194 studies examining muscular outcomes in cancer patients by searching PubMed and EMBASE databases.

RESULTS: Muscle dysfunction is evident across all stages of the cancer trajectory. The causes of cancer-related muscle dysfunction are complex, but may involve a wide range of tumor-, therapy- and/or lifestyle-related factors, depending on the clinical setting of the individual patient. The main importance of muscle dysfunction in cancer patients lies in the correlation to vital clinical end points such as cancer-specific and all-cause mortality, therapy complications and quality of life (QoL). Such associations strongly emphasize the need for effective therapeutic countermeasures to be developed and implemented in oncology practice. Significant progress has been made over the last decade in the field of exercise oncology, indicating that exercise training constitutes a potent modulator of skeletal muscle function in patients with cancer.

CONCLUSION: There are clear associations between muscle dysfunction and critical clinical end points. Yet there is a discrepancy between timing of exercise intervention trials, which can improve muscle function, and study populations in whom muscle function are proven prognostic important for clinical end points. Thus, future exercise trials should in early-stage patients, be powered to evaluate clinical outcomes associated with improvements in muscle function, or be promoted in advanced stage settings, aiming to reverse cancer-related muscle dysfunction, and thus potentially improve time-to-progression, treatment toxicity and survival.

OriginalsprogEngelsk
TidsskriftAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
Vol/bind25
Udgave nummer5
Sider (fra-til)947-58
Antal sider12
ISSN0923-7534
DOI
StatusUdgivet - maj 2014

ID: 44365624